Caricamento...
Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
BACKGROUND: Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, e...
Salvato in:
| Pubblicato in: | BMC Neurol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5381133/ https://ncbi.nlm.nih.gov/pubmed/28376794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-017-0850-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|